# US 2022/0024887 A1 · Ubiquitin-specific peptidase 24 inhibitor, medicinal composition including the same and method of delaying or reversing multidrug resistance in cancers using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0024887 A1
- Document ID: US20220024887A1
- Status: Published application
- Kind: A1
- Application number: 17/168,659
- Filed: 2021-02-05
- Published: 2022-01-27
- Earliest claimed: 2020-07-27
- Assignees: National Cheng Kung University
- Applicants: National Cheng Kung University
- Inventors: Chien-Chung HUNG; Ming-Jer YOUNG
- Web page: https://patentgrep.com/patent/US20220024887A1

## CPC

- C07D 279/30: with acyl radicals attached to the ring nitrogen atom
- C07C 49/825: all hydroxy groups bound to the ring
- C07C 55/06: Oxalic acid
- C07D 279/28: with other substituents attached to the ring system
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/31: Combination therapy
- C12Y 304/19012: Ubiquitinyl hydrolase 1 (3.4.19.12)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to a ubiquitin-specific peptidase 24 inhibitor, a medicinal composition including the same and a method of delaying or reversing multidrug resistance in cancers using the same. The USP24 inhibitor, which includes a shUSP24 RNA and/or a carbonyl substituted phenyl compound, can serve as a chemosensitizing agent for inhibiting the drug pump out, cancer sternness and genomic instability of cancer cells, thereby being applied to a medicinal composition and a method for delaying or reversing multidrug resistance in cancers.

## Claims

### Claim 1

A ubiquitin-specific peptidase 24 (USP24) inhibitor, comprising:
a short interfering nucleic acid (siNA), a carbonyl substituted phenyl compound and/or a salt thereof, the siNA is a short interfering ribonucleic acid (siRNA) having a sequence listed as SEQ ID NO:1, and the carbonyl substituted phenyl compound has a structure as formula (I):
In the formula (I), X1 represents a single bond or a nitrogen atom, n1 represents an integrity number of 1 or 2, Y represents a monovalent group, and X2 represents a hydrogen atom or a hydroxyl group, and the salt of the carbonyl substituted phenyl compound is selected from the group consisting of oxalate, phosphate, sulfate and chloride.

### Claim 2 (depends on 1)

The USP24 inhibitor of claim 1, wherein the X1 represents the single bond, the n represents the integrity number of 1, the X2 represents the hydroxyl group, the Y represents the monovalent group having a phenothiazine ring as formula (I-1) where * stands for a connection point to the X1:
in the formula (I-1), the R1 represents an alkylpiperazinyl group as formula (I-2) where # stands for a connection point to the nitrogen atom of the phenothiazine ring (I-1) and n2 represents an integrity number of 1 to 4:

### Claim 3 (depends on 2)

The USP24 inhibitor of claim 2, wherein the carbonyl substituted phenyl compound has a structure as formulas (I-3-1), (I-3-2) or (I-3-3):

### Claim 4 (depends on 1)

The USP24 inhibitor of claim 1, wherein the X1 represents the nitrogen atom, the n represents the integrity number of 2 as formula (I-4) where ** stands for a connection point to the carbonyl group, the X2 represents the hydrogen atom, the Y represents the monovalent group having a nitrobenzenesulfonamidyl group as formula (I-5) where * stands for a connection point to the nitrogen atom, and R2 represents a butyl group:

### Claim 5 (depends on 4)

The USP24 inhibitor of claim 4, wherein the carbonyl substituted phenyl compound has a structure as formula (I-6):

### Claim 6 (depends on 1)

The USP24 inhibitor of claim 1, wherein the siRNA is a double-stranded USP24 RNA, a short-hairpin USP24 (shUSP24) RNA, an isolated ribonucleic acid sequence or a viral siRNA construct, and the viral siRNA construct is a lentiviral siRNA construct.

### Claim 7

A medicinal composition for delaying or reversing multidrug resistance in cancers, comprising:
a chemotherapeutic drug;
a chemosensitizing agent comprising a USP24 inhibitor, wherein the USP24 inhibitor comprises a siRNA having a sequence listed as SEQ ID NO:1, a carbonyl substituted phenyl compound having a structure as formula (I) and/or a salt thereof, so as to delay or reverse multidrug resistance in a cancer cell:
in the formula (I), X1 represents a single bond or a nitrogen atom, n1 represents an integrity number of 1 or 2, Y represents a monovalent group, and X2 represents a hydrogen atom or a hydroxyl group; and
a pharmaceutically acceptable carrier.

### Claim 8 (depends on 7)

The medicinal composition of claim 7, wherein the X1 represents the single bond, the n represents the integrity number of 1, the X2 represents the hydroxyl group, the Y represents the monovalent group having a phenothiazine ring as formula (I-1) where * stands for a connection point to the X1:
in the formula (I-1), the R1 represents an alkylpiperazinyl group as formula (I-2) where # stands for a connection point to the nitrogen atom of the phenothiazine ring (I-1) and n2 represents an integrity number of 1 to 4:

### Claim 9 (depends on 8)

The medicinal composition of claim 8, wherein the carbonyl substituted phenyl compound has a structure as formula (I-3-1), (I-3-2) or (I-3-3):

### Claim 10 (depends on 7)

The medicinal composition of claim 7, wherein the X1 represents the nitrogen atom, the n represents the integrity number of 2 as formula (I-4) where ** stands for a connection point to the carbonyl group, the X2 represents the hydrogen atom, the Y represents the monovalent group having a nitrobenzenesulfonamidyl group as formula (I-5) where * stands for a connection point to the nitrogen atom, and R2 represents a butyl group:

### Claim 11 (depends on 10)

The medicinal composition of claim 10, wherein the carbonyl substituted phenyl compound has a structure as formula (I-6):

### Claim 12 (depends on 7)

The medicinal composition of claim 7, wherein the salt of the carbonyl substituted phenyl compound is selected from the group consisting of oxalate, phosphate, sulfate and chloride.

### Claim 13 (depends on 7)

The medicinal composition of claim 7, wherein the siRNA is a double-stranded USP24 RNA, and the siRNA is an isolated ribonucleic acid sequence or a viral siRNA construct.

### Claim 14 (depends on 7)

The medicinal composition of claim 7, wherein the viral siRNA construct is a lentiviral siRNA construct, and a value of m.o.i. of the lentiviral siRNA is 2.5 to 10.

### Claim 15 (depends on 7)

The medicinal composition of claim 7, wherein a dosage of the carbonyl substituted phenyl compound is 12.5 mg/kg to 25 mg/kg of body weight.

### Claim 16 (depends on 7)

The medicinal composition of claim 7, wherein the cancer cell is a solid tumor cell or a blood cancer cell, and the cancer cell is selected from the group consisting of a lung cancer cell, a nasopharyngeal carcinoma cell, a brain cancer cell, a colorectal carcinoma cell, a lymphoma cell, a leukemia cell and a multiple myeloma cell.

### Claim 17

A method for delaying or reversing multidrug resistance in cancers, comprising:
administering a medicinal composition to a cancer cell which is suspicious of a cancerous or undifferentiated phenotype expressing multidrug resistance, wherein the medicinal composition comprises:
a chemotherapeutic drug; and
a chemosensitizing agent comprising a USP24 inhibitor, wherein the USP24 inhibitor comprises a siNA, a carbonyl substituted phenyl compound and/or a salt thereof, and the siNA is a siRNA having a sequence listed as SEQ ID NO:1, and the carbonyl substituted phenyl compound has a structure as formula (I):
In the formula (I), X1 represents a single bond or a nitrogen atom, n1 represents an integrity number of 1 or 2, Y represents a monovalent group, and X2 represents a hydrogen atom or a hydroxyl group, and the salt of the carbonyl substituted phenyl compound is selected from the group consisting of oxalate, phosphate, sulfate and chloride.

### Claim 18 (depends on 17)

The method of claim 17, wherein the X1 represents the single bond, the n represents the integrity number of 1, the X2 represents the hydroxyl group, the Y represents the monovalent group having a phenothiazine ring as formula (I-1) where * stands for a connection point to the X1:
in the formula (I-1), the R1 represents an alkylpiperazinyl group as formula (I-2) where # stands for a connection point to the nitrogen atom of the phenothiazine ring (I-1) and n2 represents an integrity number of 1 to 4:

### Claim 19 (depends on 18)

The method of claim 18, wherein the carbonyl substituted phenyl compound has a structure as formulas (I-3-1), (I-3-2) or (I-3-3):

### Claim 20 (depends on 17)

The method of claim 17, wherein the X1 represents the nitrogen atom, the n represents the integrity number of 2 as formula (I-4) where ** stands for a connection point to the carbonyl group, the X2 represents the hydrogen atom, the Y represents the monovalent group having a nitrobenzenesulfonamidyl group as formula (I-5) where * stands for a connection point to the nitrogen atom, and R2 represents a butyl group:
and
the carbonyl substituted phenyl compound has a structure as formula (I-6):
